F. Binder-foucard, Estimation nationale de l'incidence et de la mortalité par cancer en France entre, 1980.

A. Bouvier, Z. Uhry, V. Jooste, A. Drouillard, L. Remontet et al., Focus on an unusual rise in pancreatic cancer incidence in France, Int J Epidemiol, vol.01, issue.6, pp.1764-72, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01541663

A. Cowppli-bony, Survie des personnes atteintes de cancers en France métropolitaine, 1989.

J. Ferlay, C. Partensky, and F. Bray, More deaths from pancreatic cancer than breast cancer in the EU by 2017, Acta Oncol Stockh Swed, vol.55, issue.9, pp.1158-60, 2016.

S. Iodice, S. Gandini, P. Maisonneuve, and A. B. Lowenfels, Tobacco and the risk of pancreatic cancer: a review and meta-analysis, Langenbecks Arch Surg. juill, vol.393, issue.4, pp.535-580, 2008.

G. J. Tranah, E. A. Holly, F. Wang, and P. M. Bracci, Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area, BMC Cancer. 15 avr, vol.11, p.138, 2011.

J. M. Genkinger, D. Spiegelman, K. E. Anderson, L. Bergkvist, L. Bernstein et al.,

P. A. Brandt, Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. mars, vol.18, issue.3, pp.765-76, 2009.

A. E. Becker, Y. G. Hernandez, H. Frucht, and A. L. Lucas, Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection, World J Gastroenterol WJG. 28 août, vol.20, issue.32, pp.11182-98, 2014.

T. Stocks, K. Rapp, T. Bjørge, J. Manjer, H. Ulmer et al., Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts, PLoS Med. déc, vol.6, issue.12, p.1000201, 2009.

D. K. Andersen, M. Korc, G. M. Petersen, G. Eibl, D. Li et al., Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer, Diabetes, vol.66, issue.5, pp.1103-1113, 2017.

R. Huxley, A. Ansary-moghaddam, B. De-gonzález, A. Barzi, F. Woodward et al.,

, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer. 6 juin, vol.92, issue.11, pp.2076-83, 2005.

K. M. Flegal, B. I. Graubard, D. F. Williamson, and M. H. Gail, Cause-specific excess deaths associated with underweight, overweight, and obesity, JAMA, vol.298, issue.17, pp.2028-2065, 2007.

G. K. Reeves, K. Pirie, V. Beral, J. Green, E. Spencer et al., Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study, BMJ, vol.29, issue.7630, p.1134, 2007.

E. E. Calle, C. Rodriguez, K. Walker-thurmond, and M. J. Thun, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med. 24 avr, vol.348, issue.17, pp.1625-1663, 2003.

S. C. Larsson, N. Orsini, and A. Wolk, Body mass index and pancreatic cancer risk: A metaanalysis of prospective studies, Int J Cancer. 1 mai, vol.120, issue.9, pp.1993-2001, 2007.

M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, Insulin-like growth factors and neoplasia, Nat Rev Cancer. juill, vol.4, issue.7, pp.505-523, 2004.

R. Van-kruijsdijk, E. Van-der-wall, and F. Visseren, Obesity and cancer: the role of dysfunctional adipose tissue, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.18, issue.10, pp.2569-78, 2009.

R. H. Hruban, M. Canto, M. Goggins, R. Schulick, and A. P. Klein, Update on Familial Pancreatic Cancer, Adv Surg, vol.44, pp.293-311, 2010.

L. T. Amundadottir, S. Thorvaldsson, D. F. Gudbjartsson, P. Sulem, and K. Kristjansson,

S. Arnason, Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family, PLoS Med [Internet]. déc, vol.1, issue.3, pp.1433-1440, 1993.

A. Ekbom, J. K. Mclaughlin, B. M. Karlsson, O. Nyrén, G. Gridley et al.,

, Pancreatitis and pancreatic cancer: a population-based study, J Natl Cancer Inst. 20 avr, vol.86, issue.8, pp.625-632, 1994.

J. R. Bergquist, C. A. Puig, C. R. Shubert, R. T. Groeschl, E. B. Habermann et al., Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study, J Am Coll Surg, vol.223, issue.1, pp.52-65, 2016.

S. Aoki, F. Motoi, Y. Murakami, M. Sho, S. Satoi et al., Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients, BMC Cancer. 21 mars, vol.19, issue.1, p.252, 2019.

G. Morana, L. Cancian, P. Mucelli, R. Cugini, and C. , Staging cancer of the pancreas, Cancer Imaging. 29 sept, vol.10, issue.1A, pp.137-178, 2010.

A. Schneider, H. E. Adamek, G. Layer, J. F. Riemann, and J. C. Arnold, Staging of abdominal metastases in pancreatic carcinoma by diagnostic laparoscopy and magnetic resonance imaging, Z Gastroenterol. août, vol.41, issue.8, pp.697-702, 2003.

E. S. Lee and J. M. Lee, Imaging diagnosis of pancreatic cancer: a state-of-the-art review, World J Gastroenterol. 28 juin, vol.20, issue.24, pp.7864-77, 2014.

S. R. Puli, M. L. Bechtold, J. L. Buxbaum, and M. A. Eloubeidi, How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review, Pancreas. janv, vol.42, issue.1, pp.20-26, 2013.

O. Banafea, F. P. Mghanga, J. Zhao, R. Zhao, and L. Zhu, Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses: a meta-analysis of diagnostic accuracy studies, BMC Gastroenterol. 31 août, vol.16, p.108, 2016.

S. J. Yeo, C. M. Cho, M. K. Jung, A. N. Seo, and H. I. Bae, Comparison of the Diagnostic Performances of Same-session Endoscopic Ultrasound-and Endoscopic Retrograde Cholangiopancreatography-guided Tissue Sampling for Suspected Biliary Strictures at Different Primary Tumor Sites, Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi. 25 avr, vol.73, issue.4, pp.213-221, 2019.

M. Katz, P. Pisters, D. B. Evans, C. C. Sun, J. E. Lee et al., Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease, J Am Coll Surg. 1 mai, vol.206, issue.5, pp.833-879, 2008.

M. A. Tempero, J. P. Arnoletti, S. W. Behrman, E. Ben-josef, A. B. Benson et al.,

, Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines, J Natl Compr Cancer Netw JNCCN. 1 juin, vol.10, issue.6, pp.703-716, 2012.

M. B. Ujiki and M. S. Talamonti, Guidelines for the surgical management of pancreatic adenocarcinoma, Semin Oncol. août, vol.34, issue.4, pp.311-331, 2007.

H. Friess, J. Kleeff, L. Fischer, M. Müller, and M. W. Büchler,

, Chir Z Alle Geb Oper Medizen. mars, vol.74, issue.3, pp.183-90, 2003.

O. Farges, N. Bendersky, S. Truant, J. R. Delpero, F. R. Pruvot et al., The Theory and Practice of Pancreatic Surgery in France, Ann Surg, vol.266, issue.5, pp.797-804, 2017.

J. P. Neoptolemos, J. A. Dunn, D. D. Stocken, J. Almond, K. Link et al., Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial, Lancet Lond Engl, vol.358, issue.9293, pp.1576-85, 2001.

J. P. Neoptolemos, D. D. Stocken, H. Friess, C. Bassi, J. A. Dunn et al., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med. 18 mars, vol.350, issue.12, pp.1200-1210, 2004.

H. Oettle, P. Neuhaus, A. Hochhaus, J. T. Hartmann, K. Gellert et al.,

, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, vol.310, issue.14, pp.1473-81, 2013.

J. P. Neoptolemos, D. H. Palmer, P. Ghaneh, E. E. Psarelli, J. W. Valle et al., Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet Lond Engl, vol.11, pp.1011-1035, 2017.

T. Conroy, P. Hammel, M. Hebbar, B. Abdelghani, M. Wei et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, N Engl J Med. 20 déc, vol.379, issue.25, pp.2395-406, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02281628

M. A. Tempero, M. Reni, H. Riess, U. Pelzer, E. M. O'reilly et al., APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma, J Clin Oncol. 20 mai, vol.37, pp.4000-4000, 2019.

F. Petrelli, A. Coinu, K. Borgonovo, M. Cabiddu, M. Ghilardi et al.,

, FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies, Pancreas. mai, vol.44, issue.4, pp.515-536, 2015.

M. Suker, B. R. Beumer, E. Sadot, L. Marthey, J. E. Faris et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol. juin, vol.17, issue.6, pp.801-811, 2016.

P. Hammel, F. Huguet, J. Van-laethem, D. Goldstein, B. Glimelius et al., Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study, J Clin Oncol. 20 juin, vol.31, pp.4003-4003, 2013.

F. Huguet, P. Hammel, D. Vernerey, D. Goldstein, J. L. Van-laethem et al., Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study, J Clin Oncol. 20 mai, vol.32, pp.4001-4001, 2014.

H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg et al.,

, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol Off J Am Soc Clin Oncol. juin, vol.15, issue.6, pp.2403-2416, 1997.

D. Ciliberto, C. Botta, P. Correale, M. Rossi, M. Caraglia et al., Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials, 48. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | NEJM, vol.49, pp.593-603, 1990.

D. Sur,

L. Dahan, J. M. Phelip, L. Malicot, K. Williet, N. Desrame et al., FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX), J Clin Oncol. 20 mai, vol.36, issue.15_suppl, pp.4000-4000, 2018.

V. Hoff, D. D. Ervin, T. Arena, F. P. Chiorean, E. G. Infante et al., Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, N Engl J Med, vol.369, issue.18, pp.1691-703, 2013.

T. Golan, P. Hammel, M. Reni, E. Van-cutsem, T. Macarulla et al.,

, Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer, N Engl J Med. 25 juill, vol.381, issue.4, pp.317-344, 2019.

M. Dagher, M. Sabidó, and Y. Zöllner, Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies, J Cancer Res Clin Oncol. août, vol.145, issue.8, pp.2105-2119, 2019.

R. M. Goldberg, I. Tabah-fisch, H. Bleiberg, A. De-gramont, C. Tournigand et al., Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol. 1 sept, vol.24, issue.25, pp.4085-91, 2006.

T. S. Riall, K. M. Sheffield, Y. Kuo, C. M. Townsend, J. S. Goodwin et al., Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands, Acta Oncol Stockh Swed, vol.59, issue.4, pp.278-85, 2011.

O. Turrini, F. Paye, P. Bachellier, A. Sauvanet, S. Cunha et al., Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French Surgical Association, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. févr, vol.39, issue.2, pp.171-179, 2013.

T. Sugiura, Y. Okamura, T. Ito, Y. Yamamoto, R. Ashida et al., Impact of Patient Age on the Postoperative Survival in Pancreatic Head Cancer, Ann Surg Oncol, vol.24, issue.11, pp.3220-3228, 2017.

O. Gangl, U. Fröschl, and R. Függer, Surgical quality data and survival after pancreatic cancer resections: a comparison of results for octogenarians and younger patients, Wien Klin Wochenschr. déc, vol.126, pp.757-61, 2014.

S. Marmor, E. E. Burke, B. A. Virnig, E. H. Jensen, and T. M. Tuttle, A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas, Cancer, vol.15, issue.21, pp.3378-85, 2016.

S. H. Shin, Y. Park, D. W. Hwang, K. B. Song, J. H. Lee et al., Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer, Anticancer Res. févr, vol.39, issue.2, pp.2840-2849, 2017.

D. Goldstein, R. H. El-maraghi, P. Hammel, V. Heinemann, V. Kunzmann et al., nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial, J Natl Cancer Inst. févr, vol.107, issue.2, 2015.

O. Hentic, C. Dreyer, V. Rebours, M. Zappa, P. Lévy et al., Gemcitabine in elderly patients with advanced pancreatic cancer, World J Gastroenterol. 14 août, vol.17, issue.30, pp.3497-502, 2011.

R. Maréchal, A. Demols, F. Gay, V. De-maertelaer, M. Arvanitaki et al., Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer, Pancreas. avr, vol.36, issue.3, pp.16-21, 2008.

D. Sur,

J. R. Ogden, H. Xie, W. W. Ma, and J. M. Hubbard, The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatr Basel Switz, vol.3, 2018.

D. L. Van-abbema, M. Van-den-akker, M. L. Janssen-heijnen, F. Van-den-berkmortel, A. Hoeben et al., Patient-and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review, J Geriatr Oncol. janv, vol.10, issue.1, pp.31-41, 2019.

C. Baldini, A. Escande, O. Bouché, E. Hajbi, F. Volet et al., Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis, Pancreatol Off J Int Assoc Pancreatol IAP Al. févr, vol.17, issue.1, pp.146-155, 2017.

A. K. Berger, G. M. Haag, M. Ehmann, A. Byl, D. Jäger et al., Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient, BMC Gastroenterol. 6 déc, vol.17, issue.1, p.143, 2017.

W. M. Hryniuk, More is better, J Clin Oncol. 1 sept, vol.6, issue.9, pp.1365-1372, 1988.

H. Y. Ngan, Y. C. Choo, M. Cheung, L. C. Wong, H. K. Ma et al., A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group, Chemotherapy, vol.35, issue.3, pp.221-228, 1989.

S. B. Kaye, J. Paul, J. Cassidy, C. R. Lewis, I. D. Duncan et al., Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group, J Clin Oncol Off J Am Soc Clin Oncol. juill, vol.14, issue.7, pp.2113-2122, 1996.

A. Da-rocha-lino, C. M. Abrahão, R. M. Brandão, J. R. Gomes, A. M. Ferrian et al.,

. Mcc, Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis, J Gastrointest Oncol, vol.6, issue.5, pp.511-516, 2015.

J. Viaud, C. Brac, P. Artru, L. Pabic, E. Leconte et al., Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. juin, vol.49, issue.6, pp.692-698, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01534249

H. Zhang, C. Kellett, P. Lambert, and C. A. Kim, Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience, Clin Colorectal Cancer, vol.17, issue.3, pp.451-457, 2018.

B. Tingstedt, P. Johansson, B. Andersson, and R. Andersson, Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response, Scand J Gastroenterol. juin, vol.42, issue.6, pp.754-763, 2007.

X. An, P. Ding, Y. Li, F. Wang, Y. Shi et al., Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer, Biomark Biochem Indic Expo Response Susceptibility Chem. sept, vol.15, issue.6, pp.516-538, 2010.

. Serment-d'hippocrate, Au moment d'être admise à exercer la médecine

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et

, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque